MX2023004275A - Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. - Google Patents

Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.

Info

Publication number
MX2023004275A
MX2023004275A MX2023004275A MX2023004275A MX2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antigen
binding protein
protein constructs
binding
Prior art date
Application number
MX2023004275A
Other languages
English (en)
Inventor
Yi Yang
Yuelei Shen
Baihong Liu
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of MX2023004275A publication Critical patent/MX2023004275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta divulgación se refiere a constructos de proteína de unión a antígeno (por ejemplo, anticuerpos biespecíficos o fragmentos de unión a antígeno de los mismos), en donde los constructos de proteína de unión a antígeno se unen específicamente a dos antígenos diferentes (por ejemplo, PD-1 y CD40).
MX2023004275A 2020-10-14 2021-10-13 Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. MX2023004275A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120918 2020-10-14
CN2021085335 2021-04-02
PCT/CN2021/123438 WO2022078357A1 (en) 2020-10-14 2021-10-13 Anti-pd-1/cd40 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004275A true MX2023004275A (es) 2023-05-02

Family

ID=81207517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004275A MX2023004275A (es) 2020-10-14 2021-10-13 Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230220082A1 (es)
EP (1) EP4229096A1 (es)
JP (1) JP2023545521A (es)
KR (1) KR20230092932A (es)
CN (1) CN116390755A (es)
AU (1) AU2021359495A1 (es)
BR (1) BR112023006989A2 (es)
CA (1) CA3197463A1 (es)
IL (1) IL302042A (es)
MX (1) MX2023004275A (es)
WO (1) WO2022078357A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624372A (zh) * 2022-08-26 2024-03-01 北京天广实生物技术股份有限公司 靶向cd40和pd-l1的抗体及其用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
WO2024059901A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd A method of rescuing exhausted immune cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113301919A (zh) * 2018-11-13 2021-08-24 Jn生物科学有限责任公司 激活免疫细胞的双特异性抗体

Also Published As

Publication number Publication date
KR20230092932A (ko) 2023-06-26
CA3197463A1 (en) 2022-04-21
JP2023545521A (ja) 2023-10-30
WO2022078357A1 (en) 2022-04-21
IL302042A (en) 2023-06-01
BR112023006989A2 (pt) 2024-01-02
EP4229096A1 (en) 2023-08-23
AU2021359495A1 (en) 2023-04-13
CN116390755A (zh) 2023-07-04
US20230220082A1 (en) 2023-07-13

Similar Documents

Publication Publication Date Title
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
MX2023004275A (es) Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
MD3353212T2 (ro) Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
AU2017297138A8 (en) Anti-PD-1 antibodies, method for producing same and method for using same
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
WO2016014688A3 (en) Anti-pd-1 antibodies
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
EP3786183A3 (en) Antigen binding constructs to cd3
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
MX2023004054A (es) Anticuerpos anti-dectina 1 y metodos de uso de los mismos.
MX2021012962A (es) Anticuerpo monoclonal que se une especificamente a gitr.
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos